Navigation Links
aTyr Pharma Appoints Catharine E. Johnson As Senior Vice President of Business Development
Date:6/14/2010

SAN DIEGO, June 14 /PRNewswire/ -- aTyr Pharma, Inc. today announced that Catharine E. Johnson, Ph.D. has recently joined the company as its Senior Vice President of Business Development.  Dr. Johnson's extensive biotechnology industry experience will help to advance aTyr Pharma's portfolio of resectin-based therapeutics. Resectins are a novel class of endogenous human proteins derived from aminoacyl tRNA synthetases, and have activities relevant to multiple disease areas, including autoimmunity, inflammation, and blood disorders. The privately held biotech was co-founded by Dr. Xianglei Yang and Dr. Paul Schimmel, a leading aminoacyl tRNA synthetase scientist and serial entrepreneur in the biotech sector.

Dr. Johnson brings a broad range of strategy and business development experience to aTyr. She was most recently Vice President, Corporate Development at Momenta Pharmaceuticals, Inc. (MNTA), where she managed corporate strategy and negotiated transactions related to the company's proprietary technology platform and product portfolio, including significant transactions with Novartis AG/Sandoz.  Dr. Johnson was previously a Principal at Atlas Venture, where she was responsible for new biotech investments and the management of portfolio companies.  She also served as head of business development at Regeneron Pharmaceuticals, where she was responsible for new business initiatives, strategic partnering, and alliance management, and her activities included key transactions with Novartis, Aventis, and Serono.  Dr. Johnson received her Doctorate from the Johns Hopkins School of Medicine's Department of Biological Chemistry.

"Catharine is an important addition to our senior management team," said Jeff Watkins, aTyr Pharma's Chief Executive Officer, adding "She brings extensive expertise in a variety of functions essential for building a strong and sustainable biotech company, and will bring substantial value to aTyr as we build our product portfolio and select strategic partners."

"Resectins are an enormous opportunity for the development of new medicines, and it is a privilege to be a part of such promising new science.  I am excited to work along side such a talented and committed management team, backed by experienced investors and successful scientific founders," said Dr. Johnson.  "Overlooked by the human genomics efforts, and with activities that are differentiated from existing therapies and common pharmaceutical discovery targets, the resectins represent a wealth of completely novel product opportunities.  The establishment of a select set of strategic partnerships will be a significant catalyst for aTyr's growth, and will enable the company to fully capture the value underlying aTyr's novel source of the resectin human proteins and drug targets."

About aTyr Pharma

aTyr Pharma engages in the generation of innovative therapeutics based on a new class of naturally occurring human proteins.  These proteins, called resectins, modulate extracellular signaling pathways in a variety of biological processes.  Resectins, previously overlooked by genomic efforts due to their hidden intra-protein location in ancient aminoacyl tRNA synthetase genes, have recently been discovered by aTyr, which is leading to connections in human physiology and pathophysiology ranging from inflammation to metabolic disease to peripheral neuropathy to blood disorders.  Resectin biology is distinct from currently known pathways and pharmaceutical targets and thus represents breakthrough opportunities for novel therapeutic interventions.  Tmax, aTyr's first program, is a preclinical replacement protein candidate with a novel thrombopoietic activity for the treatment of thrombocytopenia.  aTyr Pharma has established a dominant intellectual property estate surrounding resectin based compositions and therapeutic applications.

The privately held biotech was founded by Dr. Paul Schimmel, a leading aminoacyl tRNA synthetase scientist and biotechnology entrepreneur who is also a founder of Alkermes (ALKS), Cubist (CBST), Alnylam (ALNY), Sirtris (acquired by GlaxoSmithKline, GSK), Momenta Pharmaceuticals (MNTA), and Repligen (RGEN), and a founding SAB member of Illumina (ILMN). aTyr Pharma is backed by leading life sciences investors Alta Partners, Cardinal Partners, and Polaris Ventures.  For more information please visit www.atyrpharma.com


'/>"/>
SOURCE aTyr Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmatech Oncology to Present at 46th Annual DIA Meeting
2. Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer
3. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
4. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
5. Amylin Pharmaceuticals to Present at the 2010 Jefferies Global Life Sciences Conference
6. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
7. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
8. Diplomat Specialty Pharmacy Launches New Navigator Health Services to Meet Next Generation Needs of Specialty Pharmacy Industry
9. BioMed Realty Trust Breaks Ground on 176,000 Square Foot R&D Facility for Isis Pharmaceuticals in Carlsbad, California
10. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
11. University of Maryland School of Pharmacy Adopts BioSoteria's eLearning Drug Safety Courses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... For ... has won a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled ... Volunteer Experience from US2020. , US2020’s mission is to change the trajectory of ...
(Date:10/10/2017)... Oct. 10, 2017 SomaGenics announced the receipt ... to develop RealSeq®-SC (Single Cell), expected to be the ... RNAs (including microRNAs) from single cells using NGS methods. ... need to accelerate development of approaches to analyze the ... "New techniques for measuring levels of mRNAs in ...
(Date:10/9/2017)...  BioTech Holdings announced today identification and patenting ... stem cell therapy prevents limb loss in animal ... that treatment with ProCell resulted in more than ... to standard bone marrow stem cell administration.  Interestingly, ... of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving ... marijuana products targeting the needs of consumers who are incorporating medical marijuana into ... in Phoenix, Arizona. , As operators of two successful Valley dispensaries, The Giving ...
Breaking Biology Technology:
(Date:5/16/2017)... May 16, 2017  Veratad Technologies, LLC ( www.veratad.com ... age and identity verification solutions, announced today they will ... 2017, May 15 thru May 17, 2017, in ... International Trade Center. Identity impacts the ... in today,s quickly evolving digital world, defining identity is ...
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
Breaking Biology News(10 mins):